Kamtek

Yiseng US Biopharma is a global biopharmaceutical company specializing in the discovery, development, manufacturing, and commercialization of vaccines and therapeutic biologics for infectious diseases and cancer. With a dedicated team of over 800 employees and a presence in multiple countries, including China, Singapore, the United States, the United Arab Emirates, and the Philippines, Yiseng US Biopharma utilizes its proprietary PIKA immunomodulating technology platform to develop a diverse range of biotherapeutics targeting diseases such as COVID-19, hepatitis B, rabies, flu, and various forms of cancer. Through their PIKA technology, which activates multiple pathways of immune signaling, including TLR3, RIG-I, and MDA5, Yiseng US Biopharma is at the forefront of developing innovative antiviral vaccines, antiviral therapeutics, and anticancer therapeutics. Their pipeline includes PIKA-based vaccines for infectious diseases and PIKA-based immuno-oncology candidates that have demonstrated potent antitumor effects in preclinical studies. With a strong focus on advancing novel immunotherapeutics, Yiseng US Biopharma is committed to making significant contributions to the field of biopharmaceuticals.Generated from the website

Capital Biosciences, Inc. is a specialized provider located in Gaithersburg, MD, that focuses on advanced biotechnology products and services, including liquid biopsies and exosome isolation. Their expertise extends to RNA and DNA isolation, offering tailored kits and custom services for a variety of research applications. In addition to their innovative products, the company offers comprehensive custom projects, including cell line development and lentivirus production. Capital Biosciences aims to support researchers with a range of biospecimens, assays, and technical inquiries, ensuring reliable solutions for complex biological challenges. Generated from the website

Integrated Biotherapeutics Inc in Rockville is dedicated to the research and development of innovative vaccines and therapeutics for emerging infectious diseases. Their team of researchers and managers are committed to advancing the field of biotechnology. Stay informed with the latest updates and publications from IBT to learn more about their cutting-edge discoveries and contributions to the scientific community. Generated from their website's infomation